Stereotaxis Stock News

Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Stereotaxis, Inc. (NYSE:STXS ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Frank T

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulato

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu

ST. LOUIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have bee

LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington,

ST. LOUIS, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis

Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter

ST. LOUIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

Stereotaxis, Inc. (NYSE:STXS ) Q2 2023 Earnings Conference Call August 10, 2023 10:00 AM ET Company Participants David Fischel - Chairman & Chief Executive Officer Kimberly Peery - Chief Financial Off

ST. LOUIS, July 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

Stereotaxis Inc. (STXS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es